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from the cetuximab–chemotherapy combination 
was observed in the high EGFR expression group 
(immunohistochemistry score of ≥200; hazard 
ratio [HR] 0.79) versus no benefit in the low EGFR 
expression group (HR, 0.98). PFS and TTF were 
similar across treatment and EGFR expression groups, 
whereas higher response rate was found in high 
expression group in these patients receiving cetuximab–
chemotherapy combination versus chemotherapy 
alone (39.5% versus 27.4%). Findings from relatively 
small number of patients with EGFR mutations 
showed that a survival benefit may have derived from 
cetuximab–chemotherapy combination in the high 
EGFR expression group. Median survival of this 
group versus chemotherapy alone was 21.9 versus 19.5 
months (HR, 0.74), whereas the same comparison for 
the low EGFR expression group was 12.3 versus 23.8 
months (HR, 1.82). In patients with EGFR mutations, 
improved PFS, TTF, and response rates were observed 
across EGFR expression groups receiving cetuximab–
chemotherapy combination versus chemotherapy alone. 
Taken together, EGFR mutation status did not affect the 
survival advantage of combining cetuximab in first-line 
chemotherapy for patients with advanced non– small-
cell lung cancer expressing high levels of EGFR. High 
EGFR expression is a potential biomarker in predicting 
the clinical outcome of this combination treatment in 
the study population. (p. 717)
•	 Molecular Mechanisms 
Underlying Oncogenic 
RET Fusion in Lung 
Adenocarcinoma
illegitimate joining of DNA ends. Eighteen RET 
breakpoints were evaluated, of which, 16 were 
discovered from the 671 LADC cases screened. The 
finding of the location of 17 of the 18 RET breakpoints 
in a 2.0-kb region between exon 11 and intron 11 
with no breakpoint within four base pair of each other 
implied that RET fusion could be induced by the 
generation of DNA strand breaks at nonspecific sites in 
this region. Simple reciprocal inversion and DNA repair 
mechanisms (nonhomologous end joining and  break-
induced replication) that involves illegitimate joining 
of DNA ends were found to have contributed to 10 of 
18 RET fusions in LADC. The results demonstrated 
multiple mechanisms driving oncogenic RET fusions 
in LADC, which involves illegitimate repair of DNA 
strand breaks via different mechanisms to those in 
papillary thyroid carcinoma. (p. 622)
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Survival benefits of combining cetuximab to chemotherapy were 
reported in the phase III FLEX trial in patients with advanced 
non–small-cell lung cancer expressing increased levels of EGFR 
(immunohistochemistry score of ≥200; scale 0–300). The current 
analysis was aimed to investigate the effect of tumor EGFR 
mutation status on the activity of cetuximab–chemotherapy 
combination observed in the FLEX study population. Efficacy 
end points such as overall survival time, progression-free survival 
(PFS) time, objective response, and time-to-treatment failure 
(TTF) were included. Of the 971 FLEX study patients screened 
for tumor mutations, EGFR mutations (exons, 18–21) were 
found in 14% of them. Tumors with EGFR mutations showed 
improved median survival and response rate versus EGFR  wild-
type tumors in both chemotherapy plus cetuximab (17.3 versus 
9.6 months; 54.5% versus 32.9%) and chemotherapy alone (19.8 
versus 9.6 months; 35.8% versus 27.0%). Findings from patients 
with EGFR wild-type tumors revealed that a survival benefit 
This study analyzed the mechanism of oncogenic RET fusion, 
which was recognized as a driver mutation for the development 
of lung adenocarcinoma (LADC). Genomic polymerase chain 
reaction and a next-generation sequencer were used to analyze 
genomic segments with breakpoint junctions for RET fusions 
and to determine the mechanisms for DNA strand breaks and 
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•	 ITMIG Consensus 
Statement on the Use of 
the WHO Histological 
Classification of Thymoma 
and Thymic Carcinoma: 
Refined Definitions, 
Histological Criteria and 
Reporting
of morphological overlap between some thymoma 
subtypes and TC. A team of 18 pathologists, two 
surgeons, and an oncologist reviewed 72 hematoxylin 
and eosin–stained and immunohistochemically processed 
sections of prototypic and difficult-to-classify thymic 
epithelial tumors (“borderland” and “combined” 
thymomas and TC) at an international consensus slide 
workshop. Consensus was achieved on refined criteria 
for A/AB “borderland,” distinguishing B1, B2, and B3 
thymomas, and separation of B3 thymomas from TCs. 
A new type A thymoma variant, namely “atypical type 
A thymoma,” has emerged tentatively. New reporting 
strategies for tumors with more than one histological 
pattern are recommended. Although the proposed new 
criteria and guidelines need to be tested and validated in 
further studies, they set the stage for reproducibility and 
improvement of the prognostic and predictive values of 
the WHO classification. (p. 596)
history of lung adenocarcinoma, who had computer 
tomography–guided fine-needle aspiration of ground-
glass lesions suspicious for early adenocarcinoma, 
were identified for the study. Of the 16 patients opted 
to observe their ground-glass lesions with suspicious 
cytology results, 37.5% eventually had growth or 
increase in solid component of the ground-glass lesion. 
Of these, five patients underwent surgical resection 
or radiation therapy. No distant metastasis or lung 
cancer–associated deaths were found in the observed 
group. In 47 patients opted for immediate resection 
after abnormal cytology results, metastasis (n = 2), 
new cancers in remaining lung (n = 5), and existing 
ground-glass lesion progression (n = 3) were observed. 
This study indicates that watchful waiting after ground-
glass lesion biopsy did not show higher metastatic 
rates or cancer-related deaths and suggests that delayed 
resection does not deteriorate the outcomes. (p. 685)
•	 Outcomes of Unresected 
Ground-Glass Nodules with 
Cytology Suspicious for 
Adenocarcinoma
Gulati et al. conducted a study to compare the clinical outcomes of 
patients who were resected immediately after abnormal cytology 
results suspicious for early lung adenocarcinoma and those who 
selected watchful waiting. Sixty-three patients without prior 
The World Health Organization (WHO) classification (2004) assigns 
thymic epithelial tumors into A, AB, B1, B2, and B3 and (rare other) 
thymomas and thymic carcinomas (TC) based on fundamental 
morphological differences. Nevertheless, poor interobserver 
reproducibility or inconsistencies in some studies prompted the 
organization of an interdisciplinary panel by the International 
Thymic Malignancy Interest Group to refine histological criteria 
while maintaining the WHO classification for better management 
RESEARCH WATCH
•	 The Potential Effects of 
Tobacco Control in China: 
Projections from the China 
SimSmoke Simulation Model
The authors sought to project the potential impact of 
complete implementation of tobacco control in China 
as recommended by the World Health Organization 
Framework Convention on Tobacco Control via computer 
simulation model. In a study population of men and 
women aged 15 to 74 years, current and former smoking 
prevalence, initiation and cessation rates, and past policy 
levels were included to predict past smoking rates and 
project future status quo rates. The model projected future 
Photo credit: Dr. Usman Bashir, with no 
modifications from Radiopaedia.org under 
Creative Commons Attribution-Noncommercial-
Share Alike 3.0 Unported licence.
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smoking prevalence to decrease from 51.3% (men) 
or 2.1% (women) in 2015 to 46.5% (men) or 1.3% 
(women) by 2050. The most efficient tobacco control 
policy was by raising the tobacco excise tax to 75% 
of the retails price, resulting in incremental decline by 
12.9% in current smoking versus the status quo by 2050. 
Approximately 40% of incremental decline in smoking 
versus the status quo, the prevention of approximately 
12.8 million smoking attributable deaths, and the loss of 
154 million life years by 2050 were projected through 
complete implementation of all Framework Convention 
on Tobacco Control policies in China.
Levy D, Rodriguez-Buno RL, Hu TW, Moran AE. 
The potential effects of tobacco control in China: 
projections from the China SimSmoke simulation 
model. BMJ 2014;348:g1134.
•	 Tobacco Control Policies 
and Their Impacts. Past, 
Present, and Future
products. This article is particularly interesting in its 
review of the impact of tobacco control policies; it 
reproduces a figure drawn from U.S. Department of 
Health and Human Science reports, also reproduced 
in the leading article of this issue, a special article on 
the Surgeon Generals’ Reports from 1964 to 2014. 
This figure is reproduced below and is remarkable 
for the visual presentation of the link between policy 
introduction and the decline in cigarette smoking. The 
governmental policies include increasing cigarette 
price, which effectively encouraged some to quit 
smoking or cut daily consumption, and discouraged 
children from smoking initiation. Dramatic impacts 
from  smoke-free workplace policies were also 
observed: reduced workers’ exposure to cigarette smoke 
toxins, employers’ costs, and the incidence of acute 
myocardial infarctions. Future new and radical tobacco 
control approaches are warranted to ensure continuing 
success and achieve a smoke-free society.
•	 Noninvasive Detection of 
Response and Resistance 
in EGFR-Mutant Lung 
Cancer Using Quantitative 
Next-Generation 
Genotyping of Cell-Free 
Plasma DNA
patient populations: advanced non–small-cell lung 
cancer (NSCLC) harboring EGFR or KRAS mutation 
and advanced melanoma with BRAF mutation. 
Positive and negative controls using cancers with 
nonoverlapping genotypes were included to evaluate 
sensitivity and specificity of the assay. Patients with 
EGFR-mutant NSCLC from a prospective trial of 
erlotinib were assessed for response and resistance 
using the assay. The assay identified EGFR L858R and 
exon 19 deletions in KRAS-mutant lung cancer with 
high sensitivity and 100% specificity. An area under 
the curve of 0.80 to 0.94 was achieved in received 
operative characteristic curve analysis of the assays. 
Optimal cfDNA concentrations improved the assay 
This abstract is drawn from the February 2014 issue of the Annals 
of the American Thoracic Society and is one of a number of 
articles in this issue examining the aspects of smoking and tobacco 
control including e-cigarettes, changing attitudes, and nicotine 
This study explored the use of cell-free plasma DNA (cfDNA) 
genotyping using droplet digital polymerase chain reaction (ddPCR) 
as a noninvasive assay in identifying biomarkers for accurate 
diagnosis and monitoring of disease status. ddPCR emulsifies DNA 
into droplets that are PCR-amplified and fluorescently labeled, 
followed by reading in an automated droplet flow cytometer to 
quantify genome prevalence. Plasma was collected from two 
Figure 2. Samet JK. Ann Am Thorac Soc 
2014;11(2):141–148.
Warner KE. Tobacco control policies and their 
impacts. Past, present, and future. Ann Am 
Thorac Soc 2014;11:227–230,  doi:10.1513/
AnnalsATS.201307-244PS.
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sensitivity. In first-line erlotinib treated patients, serial 
plasma genotyping of EGFR-mutant NSCLC detected 
pretreatment EGFR mutations, complete plasma 
response in most cases, and EGFR T790M–mediated 
acquired resistance up to 16 weeks before radiographic 
progression. Taken together, noninvasive genotyping 
of cfDNA via ddPCR has the potential as a clinical 
diagnostic for personalizing treatment of tumors with 
defined genotypes, as well as detection of response and 
resistance.
Oxnard GR, Paweletz CP, Kuang Y, et al. 
Noninvasive detection of response and resistance in 
EGFR-mutant lung cancer using quantitative  next-
generation genotyping of cell-free plasma DNA. Clin 
Cancer Res 2014;20:1698–1705,  doi:10.1158/1078-
0432.ccr-13-2482.
•	 Maintenance 
Bevacizumab–Pemetrexed 
after First-Line Cisplatin–
Pemetrexed–Bevacizumab 
for Advanced 
Nonsquamous Non– Small-
Cell Lung Cancer: Updated 
Survival Analysis of the 
AVAPERL (MO22089) 
Randomized Phase III Trial
versus the bevacizumab arm (n = 125) after a median 
follow-up of 14.8 months (7.4 versus 3.7 months; 
hazard ratio, 0.57; p < 0.0001). Overall survival (OS) 
data were available in 58% of all patients, but the 
increase in OS was not significant with bevacizumab–
pemetrexed versus bevacizumab when measured from 
randomization (17.1 versus 13.2 months; hazard ratio, 
0.87; p = 0.29). No report of new adverse events in 
this updated analysis. The findings demonstrated that 
maintenance bevacizumab–pemetrexed after the  first-
line platinum-based therapy in unselected patients 
with nonsquamous non–small-cell lung cancer 
with disease control did not achieve a significant 
improvement in OS versus bevacizumab alone.
Barlesi F, Scherpereel A, Gorbunova V, et al. 
Maintenance bevacizumab–pemetrexed after  first-
line cisplatin–pemetrexed–bevacizumab for advanced 
nonsquamous non–small-cell lung cancer: updated 
survival analysis of the AVAPERL (MO22089) 
randomized phase III trial. Ann Oncol 2014, 
doi:10.1093/annonc/mdu098.
This report is an independent and updated survival analysis 
of the AVAPERL randomized phase III trial, in which 
safety and efficacy of bevacizumab maintenance with or 
without pemetrexed in advanced nonsquamous non– small-
cell lung cancer were evaluated. After first-line treatment 
with bevacizumab, cisplatin, and pemetrexed, patients with 
no progressive disease were randomized to bevacizumab or 
bevacizumab–pemetrexed until progression. The primary end 
point was progression-free survival. Significantly prolonged 
progression-free survival, when measured from randomization, 
was observed in the bevacizumab–pemetrexed arm (n = 128) 
•	 Tumor Protein Predicts 
Response to Chemotherapy 
in Patients with Esophageal 
Cancer
gastric adenocarcinoma cell lines. From the analysis of 
radiological responding and nonresponding patients, 
gene enrichment of the 520 differentially expressed 
genes identified the adipocytokine signaling pathway 
in association with response. Higher leptin expression 
correlated with chemoresistance in the discovery 
and validation cohorts (p = 0.011 and p = 0.007, 
respectively). Similar results were observed in the gastric 
adenocarcinoma cell lines to cisplatin (p = 0.008), which 
were further supported by leptin receptor antagonist-
mediated enhanced cell line sensitivity to cisplatin. 
On the other hand, patients with high leptin expression 
Bain et al. set out to determine novel predictive biomarkers for 
chemotherapy response in patients with esophageal adenocarcinoma 
using gene expression profiling of their tumor biopsies. The 
discovery cohort consisted of tumor biopsies from 14 patients 
with tumor, node, metastasis (TNM) stage IB–IV esophageal 
adenocarcinomas treated with platinum-based chemotherapy. The 
validation cohort consisted of 154 patients undergone surgery 
with or without neoadjuvant platinum chemotherapy and 22 
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had improved survival regardless of neoadjuvant 
chemotherapy versus those with low leptin expression. 
Taken together, tumor leptin expression is a potential 
predictive marker for chemoresistance and prognostic 
marker independent of therapy in esophageal 
adenocarcinoma. Leptin antagonists in clinical use 
could be potentially explored for novel therapeutic 
intervention in esophageal adenocarcinoma.
Bain GH, Collie-Duguid E, Murray GI, et al. Tumour 
expression of leptin is associated with chemotherapy 
resistance and therapy-independent prognosis in 
gastro-oesophageal adenocarcinomas. Br J Cancer 
2014;110:1525–1534, doi:10.1038/bjc.2014.45.
•	 Preoperative 
Chemotherapy for Non–
Small-Cell Lung Cancer: 
A Systematic Review and 
Meta-Analysis of Individual 
Participant Data
decrease in the relative risk of death. It was unclear that 
this survival benefit could be affected by chemotherapy 
regimen or schedules, number of drugs, platinum 
agents used, and postoperative radiotherapy. It was 
also unclear that the improved survival by preoperative 
chemotherapy could be associated with specific patients 
stratified by age, sex, performance status, histology, 
and clinical stage. Significantly better recurrence-free 
survival (HR, 0·85, p = 0·002) and time to distant 
recurrence (HR, 0·69, p < 0·0001) were observed in 
patients with preoperative chemotherapy, most of which 
had stage 1B–IIIA. With significantly improved overall 
survival, recurrence-free survival, and time to distant 
recurrence in resectable non–small-cell lung cancer, this 
study suggests that preoperative chemotherapy is a valid 
option for treating this patient population.
Preoperative chemotherapy for non–small-cell 
lung cancer: a systematic review and meta-analysis of 
individual participant data. The Lancet 2014.
NEWS IN BRIEF
•	 Fast-Tracked Approval 
of Drugs and Tests in 
Australia
Previously in Australia, it involved two different 
review processes to list a drug in the Pharmaceutical 
Benefits Scheme (PBS) and its companion genetic tests 
in the publication Medicare Benefits Schedule (MBS). 
The Australian Government subsidizes prescription 
drugs via the PBS, and lists a variety of subsidized 
consultations, procedures, and tests in the MBS. A 
dual-approval process has enabled the listing of two 
lung cancer drugs, gefitinib and erlotinib, in the PBS 
and their companion genetic tests in the MBS, in just 
one review for the first time. This initiative means 
eligible patients gain quicker access to treatment and 
the tests at affordable costs. This approach has been 
welcome by experts, but also warrants further testing 
for definitive outcomes and close monitoring of the 
approval process.
The effect of preoperative chemotherapy for patients with resectable 
non–small-cell lung cancer was assessed in this systematic review 
and meta-analysis of individual participant data. Findings from 
15 individual randomized controlled trials which involved 2385 
patients were combined. Primary outcome was overall survival, 
that is, the time from randomization until death (any cause) or 
date of last follow-up for living patients. Secondary outcomes 
were recurrence-free survival, time to locoregional and distant 
recurrence, cause-specific survival, complete and overall resection 
rates, and postoperative mortality. A significant improvement in 
overall survival (5% at 5 years) from preoperative chemotherapy 
was observed (hazard ratio [HR] 0·87, p = 0·007), with a 13% 
Photo source: CDC
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response to sorafenib within 2 months of treatment 
and remained progression free for 5 years. A somatic 
mutation, ARAF S214C, was identified in the cancer 
genome with increased expression by whole-genome 
sequencing and RNA sequencing of patient tumor 
and normal samples. Additional ARAF mutations 
were found in 1% of an independent cohort of 
lung adenocarcinoma. A role in transformation of 
immortalized human airway epithelial cells was 
demonstrated for the ARAF mutations in a  sorafenib-
sensitive manner. The findings suggest that mutant 
ARAF is an oncogenic driver in lung adenocarcinoma 
and an indicator of sorafenib response.
•	 Patterns Shifted in the 
Interpretation of Phase III 
Clinical Trial Outcomes in 
Advanced Non–Small-Cell 
Lung Cancer
increasing use of progression-free survival as a 
surrogate for overall survival (13% rise; p = 0.002) 
as the primary study end point and a decreasing 
magnitude of survival gain in positive trials (from 3.9 
to 2.5 months; p = 0.11) in conjunction with larger 
clinical trial sample size (median n = 152 to n = 413; 
p < 0.001). Although the proportion of trials meeting 
primary end points remained stable, those showing 
positive outcome with unmet end point increased 
(from 30% to 53%; p < 0.001). The findings confirm 
a significant shift in trial design and interpretation of 
phase III trials in advanced non–small-cell lung cancer 
over the past 30 years—significant decline in using 
survival as the primary measure of outcome, and in 
clinically relevant magnitude of the outcome.
•	 Potential Novel Gene Target 
for Lung Cancer
In a brief report published in the Journal of Clinical Investigation, 
Imielinski et al. demonstrated the discovery of a new gene 
mutation that could drive lung cancer growth and development. 
One patient from the Eastern Cooperative Oncology Group 2501 
clinical study with stage IV lung cancer showed a near-complete 
A study published in Journal of Clinical Oncology analyzed the 
change in design and interpretation of 203 randomized controlled 
trials of systemic therapy for advanced non–small-cell lung 
cancer over the past 30 years. The findings revealed significantly 
•	 NEW EU LEGISLATION products in the EU. A summary press release  (http://
europa.eu/rapid/press-release_MEMO-14-134_en.htm) 
notes that the commission decided to revise previous 
rules to deal with new scientific evidence, new products 
(such as e-cigarettes), and varying regulatory approaches 
by different EU Member States. Most smokers start 
smoking when very young (particularly younger than 
25 years of age); the new rules aim to make tobacco 
consumption less attractive in the EU for young people. 
Future cigarette packs will include health warnings 
(pictures and text); slim “lipstick”-style packs will be 
banned. Similar rules will apply to roll-your-own tobacco 
packs although Member States can choose whether such 
rules apply to “low-use” tobacco products such as pipe 
tobacco, cigars, cigarillos, and smokeless products. 
Plain packaging, although not part of the Directive, 
may emerge to a limited degree at the discretion of 
Member States. Flavorings (such as menthol) will be 
banned (for menthol after a 4-year phase-out period). 
A new Tobacco Products Directive has been approved by the 
European Parliament on February 26, 2014 which strengthens the 
rules on the manufacture, production, and presentation of tobacco 
Photo credit: Mike Blackburn (http://www.flickr.
com/photos/mikeblackburn/5520196331/)
Photo credit: Ceccomaster. Available at:  http://
commons.wikimedia.org/wiki/File:Europe_-_
Mortality_rate_for_women_of_lung_cancer_
in_2006.svg
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Mandatory and standardized formatting of ingredients 
is “foreseen” including tar emissions, nicotine, and 
carbon monoxide for cigarettes. New rules will cover 
consumer e-cigarettes on the EU market and will 
include a maximum nicotine concentration, child- 
and tamper-proof cartridges, tanks and containers of 
nicotine liquids, health warnings on e-cigarette packs, 
advance notification of Member States for new products 
entering the market, annual reports from manufacturers 
to Member States (on sales volumes, types of users, 
etc.), and compliance with advertising rules. Oral 
tobacco will continue to be banned (outside of Sweden 
which has an exemption). There are tracking and tracing 
measures to be introduced to address illicit trade. Bans 
on cross-border distance sales will be at the Member 
State’s discretion. The new rules are expected to lead 
to a 2% decrease in tobacco consumption more than 
5 years (approximately 2.4 million fewer smokers) 
with an annual healthcare saving of 506 million euros. 
The new Directive will take force in May 2014 with 
a 2-year phase-in period for Member States to bring 
national legislation into line with the Directive. Further 
information is available from http://ec.europa.eu;health/
tobacco/products/index_en.htm.
